Lonza swoops in with $1.2B to take over Roche’s biologics site in California

With Lon­za an­tic­i­pat­ing per­sis­tent in­crease in de­mand for com­mer­cial bi­o­log­ics man­u­fac­tur­ing, the Swiss com­pa­ny is pick­ing up a pro­duc­tion site owned by Roche’s Genen­tech for $1.2 bil­lion in cash.

The man­u­fac­tur­er al­so has CHF 500 mil­lion ($562.5 mil­lion) in its bud­get to up­grade the Va­cav­ille, CA, fa­cil­i­ty to sup­port large-scale bi­o­log­ics pro­duc­tion for mam­malian drug sub­stances. The site has about 750 Genen­tech work­ers, who will be of­fered em­ploy­ment by the man­u­fac­tur­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.